DAVINCI
Depression and Alcoholism
Validation of an Integrated Care Initiative

# The DA VINCI Pharmacotherapy Algorithm

**Antidepressant Trials:**
Trial A - Sertraline (Fluoxetine, Venlafaxine XR, Mirtazapine -if Sertraline previously tried and failed)
Trial B - Untried drug from Trial A Group
Trial C - Untried drug from Trials A and B Groups

| Type | Medication | Dose | Week 1 of medication | | | | | | | Week 2 of medication | | | | | | | Week 3 of medication | | | | | | | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 → | Max Dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Day 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22-28 | 29-35 | 36-42 | 43-49 | 50 → | |
| Antidepressants | Sertraline | mg AM | 25 | | | | | | | 50 | | | | | | | | | | | | | | Increase dose by 50 mg every 2-4 weeks depending on tolerability and response | | | | | 200 mg/day |
| | Fluoxetine | mg AM | 10 | | | | | | | 20 | | | | | | | | | | | | | | Increase dose by 20 mg every 4 weeks depending on tolerability and response | | | | | 80 mg/day |
| | Venlafaxine XR | mg AM | 37.5 | | | | | | | 75 | | | | | | | | | | | | | | Increase dose by 75 mg every 2-4 weeks depending on tolerability and response | | | | | 375 mg/day |
| | Mirtazapine | mg QHS | 15 | | | | | | | 30 | | | | | | | | | | | | | | Increase dose by 15 mg every 2-4 weeks depending on tolerability and response | | | | | 60 mg/day |

## Tactics and Critical Decision Point and Critical Status Plan for the Treatment of Major Depressive Disorder

**STARTING POINT → Week 0** (CDP#1) QIDs ≥ 9 Symptomatic **PLAN → Initiate antidepressant medication; adjust dose to lower end of therapeutic dose rang or serum level.**

| QIDS-C16 SCORE | Week 2 of medication | Week 4 of medication | Week 6 of med. | Week 9 of med. | Week 12 of med. |
|---|---|---|---|---|---|
| QIDS ≤ 5 (Remission) | Continue current dose. | | | | Go to follow-up phase. |
| QIDS = 6-8 (Partial Response) | Gradually increase dose as tolerated. | • Continue current dose.<br>• Consider increasing dose. | Increase/maximize dose. | • Increase dose.<br>• Switch to another antidepressant. | • Switch to another antidepressant.<br>• Increase dose and reevaluate in 2 weeks. |
| QIDS = 6-8 (SEs intolerable) | • Continue current dose and address SEs.<br>• Decrease dose and continue for 2 additional weeks.<br>• Switch to another antidepressant | • Continue current dose and address SEs.<br>• Switch to another antidepressant. | • Continue current dose and address SEs.<br>• Switch to another antidepressant. | | |
| QIDS ≥ 9 (Non-response) | Gradually increase dose as tolerated. | • Increase dose.<br>• Switch to another antidepressant. | Switch to another antidepressant. | Switch to another antidepressant. | Switch to another antidepressant. |
| QIDS ≥ 9 (SEs intolerable) | • Decrease dose and continue for 2 additional weeks.<br>• Switch to another antidepressant. | • Switch to another antidepressant. | | | |

| Type | Medication | Dose | Week 1 of medication | | | | | | | Week 2 of medication | | | | | | | Week 3 of medication | | | | | | | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 → | Max Dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Day 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22-28 | 29-35 | 36-42 | 43-49 | 50 → | |
| Anticraving | Trial 1: Naltrexone | mg/day | 25 | | | | | | | 50 | | | | | | | | | | | | | | | | | | | 50 mg/day |
| | Trial 2: Acamprosate | mg TID | 333 mg TID | | 333 mg TID | | | | | 666 mg TID | | | | | | | | | | | | | | | | | | | 666 mg TID |
| | Trial 3: Topiramate | mg AM | | | | | | | | | | | | | | | 25 | | | | | | | 50 | 50 | 100 | 100 | 150 | 300 mg/day |
| | | mg PM | 25 | | | | | | | 50 | | | | | | | | | | | | | | 100 | 100 | 150 | 150 | | |

| Criteria for Anti-Craving MedicationTreatment Non-Responders | Criteria for Anti-Craving Medication Switch |
|---|---|
| Treatment non-Responder will have more than 7 (women) or 14 (men) drinks per week on average.<br>OR<br>More than 1 day on which more than 3 drinks (women) or 4 drinks (men) were consumed over the period of 2 weeks. | Being defined as a Treatment non-Responder at 3 consecutive visits will trigger a switch of anticraving medication to the next level. |